PHARMA TECHNOLOGY

PHARMA TECHNOLOGY has been active since 1991 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €16.3m and a net result of €3.8m. Equity remains stable across the filed fiscal years (±2.3% per year). Its solvency ranks better than 69% of 140 sector peers (NACE 32, fiscal year 2025). The computed 12-month bankruptcy probability is < 0.1% (very low).